Pharmaceuticals, Biotechnology and Life Sciences
Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation Sanofi.
HighTide Therapeutics said that its HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes, as HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk factors.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in mainland China from the National Medical Products Administration (NMPA) of China.
Immunogenicity Data from VAC2 Clinical Trial Supports Mechanism of Action Dendritic Cell Therapy Program Will Focus on Immuno-Oncology Platform Expansion…
– Deep clinical responses reported for two of seven patients with relapsed/refractory Ewing sarcoma treated with the recommended Phase 2…
Submission based on pivotal phase 2 DESTINY-Gastric01 and phase 1 trial data Trastuzumab deruxtecan to receive expedited review by Japan…
Received U.S. FDA Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer…
41 of the candidate drugs from AI VIVO’s top-ranked list for COVID-19 are now in clinical trials for COVID-19 by…
Trial conducted at Memorial Sloan Kettering Cancer Center designed to evaluate potential risk reduction for patients at risk for coronavirus…
Completed Enrollment in Phase 2 Trial Cohort Evaluating SY-1425 in RARA-Positive Relapsed or Refractory AML Patients On Track for 2020…